Vaxart (VXRT) Competitors $0.46 -0.05 (-9.98%) Closing price 04:00 PM EasternExtended Trading$0.46 0.00 (-0.28%) As of 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VXRT vs. ORKA, CMPS, AUTL, CYRX, CKPT, SNDL, TRDA, OLMA, ARCT, and HRTXShould you be buying Vaxart stock or one of its competitors? The main competitors of Vaxart include Oruka Therapeutics (ORKA), COMPASS Pathways (CMPS), Autolus Therapeutics (AUTL), Cryoport (CYRX), Checkpoint Therapeutics (CKPT), SNDL (SNDL), Entrada Therapeutics (TRDA), Olema Pharmaceuticals (OLMA), Arcturus Therapeutics (ARCT), and Heron Therapeutics (HRTX). These companies are all part of the "pharmaceutical products" industry. Vaxart vs. Oruka Therapeutics COMPASS Pathways Autolus Therapeutics Cryoport Checkpoint Therapeutics SNDL Entrada Therapeutics Olema Pharmaceuticals Arcturus Therapeutics Heron Therapeutics Vaxart (NASDAQ:VXRT) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, community ranking, risk, earnings, media sentiment, institutional ownership and dividends. Do analysts prefer VXRT or ORKA? Vaxart currently has a consensus target price of $3.00, suggesting a potential upside of 556.02%. Oruka Therapeutics has a consensus target price of $39.86, suggesting a potential upside of 276.72%. Given Vaxart's higher possible upside, research analysts clearly believe Vaxart is more favorable than Oruka Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxart 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Does the MarketBeat Community prefer VXRT or ORKA? Vaxart received 293 more outperform votes than Oruka Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Oruka Therapeutics an outperform vote while only 65.61% of users gave Vaxart an outperform vote. CompanyUnderperformOutperformVaxartOutperform Votes31165.61% Underperform Votes16334.39% Oruka TherapeuticsOutperform Votes18100.00% Underperform VotesNo Votes Which has more risk & volatility, VXRT or ORKA? Vaxart has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Is VXRT or ORKA more profitable? Oruka Therapeutics has a net margin of 0.00% compared to Vaxart's net margin of -431.61%. Oruka Therapeutics' return on equity of -24.96% beat Vaxart's return on equity.Company Net Margins Return on Equity Return on Assets Vaxart-431.61% -110.46% -62.78% Oruka Therapeutics N/A -24.96%-21.22% Which has higher valuation and earnings, VXRT or ORKA? Oruka Therapeutics has lower revenue, but higher earnings than Vaxart. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxart$28.70M3.64-$82.46M-$0.27-1.69Oruka TherapeuticsN/AN/A-$5.34M-$4.51-2.35 Does the media favor VXRT or ORKA? In the previous week, Oruka Therapeutics had 12 more articles in the media than Vaxart. MarketBeat recorded 20 mentions for Oruka Therapeutics and 8 mentions for Vaxart. Vaxart's average media sentiment score of 0.74 beat Oruka Therapeutics' score of 0.73 indicating that Vaxart is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxart 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in VXRT or ORKA? 18.0% of Vaxart shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 2.9% of Vaxart shares are owned by company insiders. Comparatively, 22.7% of Oruka Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryOruka Therapeutics beats Vaxart on 11 of the 18 factors compared between the two stocks. Get Vaxart News Delivered to You Automatically Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VXRT vs. The Competition Export to ExcelMetricVaxartBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$104.37M$2.93B$5.35B$8.38BDividend YieldN/A1.72%5.22%4.10%P/E Ratio-1.1230.5026.8419.71Price / Sales3.64400.15391.39116.98Price / CashN/A168.6838.2534.62Price / Book1.203.286.794.50Net Income-$82.46M-$72.17M$3.23B$248.18M7 Day Performance14.33%4.28%4.07%1.14%1 Month Performance43.76%7.62%12.52%15.18%1 Year Performance-46.82%-28.15%16.83%6.55% Vaxart Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VXRTVaxart2.3856 of 5 stars$0.46-10.0%$3.00+556.0%-43.3%$104.37M$28.70M-1.12120News CoverageORKAOruka Therapeutics2.6029 of 5 stars$9.75+2.2%$39.86+308.8%N/A$365.05MN/A-1.56N/ANews CoveragePositive NewsEarnings ReportAnalyst RevisionGap UpCMPSCOMPASS Pathways2.2275 of 5 stars$3.91+3.2%$20.20+416.6%-41.7%$363.04MN/A-1.78120Positive NewsAUTLAutolus Therapeutics3.222 of 5 stars$1.35+2.3%$9.32+590.4%-61.9%$359.23M$10.12M-1.12330High Trading VolumeCYRXCryoport3.0174 of 5 stars$7.15+1.1%$11.00+53.8%-43.2%$358.48M$214.83M-2.121,020News CoveragePositive NewsCKPTCheckpoint Therapeutics2.0613 of 5 stars$4.16-0.2%$4.33+4.2%+104.9%$348.46M$41,000.00-2.2610News CoveragePositive NewsSNDLSNDL3.0889 of 5 stars$1.32+2.3%$3.63+174.6%-44.6%$346.86M$927.61M-4.26580News CoveragePositive NewsTRDAEntrada Therapeutics2.9644 of 5 stars$8.82+5.3%$25.67+191.0%-46.2%$334.75M$172.22M5.55110News CoverageAnalyst ForecastAnalyst RevisionOLMAOlema Pharmaceuticals2.2991 of 5 stars$4.76+3.5%$27.67+481.2%-46.6%$325.40MN/A-2.1770Positive NewsGap UpARCTArcturus Therapeutics2.9583 of 5 stars$11.59+5.6%$59.20+410.8%-58.4%$314.33M$138.39M-5.22180Gap UpHRTXHeron Therapeutics3.8862 of 5 stars$2.05-2.8%$5.50+168.3%-43.5%$312.76M$148.52M-11.39300 Related Companies and Tools Related Companies Oruka Therapeutics Competitors COMPASS Pathways Competitors Autolus Therapeutics Competitors Cryoport Competitors Checkpoint Therapeutics Competitors SNDL Competitors Entrada Therapeutics Competitors Olema Pharmaceuticals Competitors Arcturus Therapeutics Competitors Heron Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VXRT) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxart With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VXRT Stock Free VXRT Stock Alerts